Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689523 | 0.86 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19GAAPOLB | |
| SCHEMBL331957 | 0.86 | CYP3A4 (0.38) | CYP3A4CYP2C9CYP2C19GAAPOLB | |
| SCHEMBL28818287 | 0.86 | LMNA (0.35) | CYP3A4CYP2C9CYP2C19GAACA12 | |
| SCHEMBL13203905 | 0.81 | CYP3A4 (0.38) | CYP3A4CYP2C9CYP2C19GAAPOLB | |
| SCHEMBL5892255 | 0.81 | GAA (0.39) | CYP3A4CYP2C9CYP2C19GAAPOLB | |
| SCHEMBL2637224 | 0.80 | POLB (0.42) | CYP3A4CYP2C9CYP2C19GAAPOLB | |
| SCHEMBL26089024 | 0.79 | CYP3A4 (0.36) | CYP3A4CYP2C9CYP2C19GAAPOLB | |
| SCHEMBL19379182 | 0.79 | CYP3A4 (0.36) | CYP3A4CYP2C9CYP2C19GAAPOLB | |
| SCHEMBL12631725 | 0.77 | ALDH1A1 (0.34) | CYP3A4CYP2C9CYP2C19GAAPOLB | |
| SCHEMBL13790227 | 0.76 | GAA (0.42) | CYP3A4CYP2C9CYP2C19GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071221-B2 | Heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2006-07-04 | — | — | US | disclosed |
| US-20050026973-A1 | New heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026973-A1 | New heterocyclic oxime compounds | CBR3, CBR1, CYB5R3 | CYP3A4 158/4885CYP2C9 61/4885CYP2C19 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.